Myokardia Inc (MYOK) Insider Joseph Lambing Sells 5,000 Shares of Stock

Myokardia Inc (NASDAQ:MYOK) insider Joseph Lambing sold 5,000 shares of the business’s stock in a transaction that occurred on Friday, January 12th. The stock was sold at an average price of $50.00, for a total transaction of $250,000.00. Following the transaction, the insider now owns 95,846 shares of the company’s stock, valued at approximately $4,792,300. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Myokardia Inc (NASDAQ:MYOK) opened at $52.00 on Wednesday. Myokardia Inc has a twelve month low of $10.55 and a twelve month high of $54.00. The stock has a market cap of $1,890.70, a price-to-earnings ratio of -68.42 and a beta of 4.21.

Myokardia (NASDAQ:MYOK) last issued its earnings results on Thursday, November 2nd. The biotechnology company reported ($0.42) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.42). Myokardia had a negative net margin of 53.49% and a negative return on equity of 14.92%. The business had revenue of $5.63 million during the quarter, compared to analysts’ expectations of $6.10 million. During the same quarter in the prior year, the business posted ($0.35) EPS. The company’s revenue for the quarter was up 58.6% on a year-over-year basis. research analysts forecast that Myokardia Inc will post -1.62 earnings per share for the current year.

Several research analysts have commented on MYOK shares. Zacks Investment Research cut shares of Myokardia from a “hold” rating to a “sell” rating in a report on Wednesday, October 11th. Credit Suisse Group reiterated an “outperform” rating and set a $55.00 price target (up previously from $45.00) on shares of Myokardia in a report on Tuesday, September 19th. TheStreet cut shares of Myokardia from a “c” rating to a “d+” rating in a report on Friday, November 3rd. JPMorgan Chase & Co. started coverage on shares of Myokardia in a report on Tuesday, December 12th. They set an “overweight” rating and a $54.00 price target for the company. Finally, BidaskClub cut shares of Myokardia from a “hold” rating to a “sell” rating in a report on Wednesday, December 20th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $54.83.

Several institutional investors have recently modified their holdings of MYOK. Nationwide Fund Advisors boosted its holdings in shares of Myokardia by 36.3% in the 2nd quarter. Nationwide Fund Advisors now owns 9,729 shares of the biotechnology company’s stock valued at $127,000 after buying an additional 2,591 shares in the last quarter. Alliancebernstein L.P. acquired a new stake in Myokardia during the 2nd quarter worth $148,000. The Manufacturers Life Insurance Company boosted its stake in Myokardia by 38.8% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 15,073 shares of the biotechnology company’s stock worth $198,000 after purchasing an additional 4,215 shares during the period. Quantbot Technologies LP acquired a new stake in Myokardia during the 3rd quarter worth $202,000. Finally, Dimensional Fund Advisors LP acquired a new stake in Myokardia during the 3rd quarter worth $212,000. Institutional investors and hedge funds own 63.61% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Myokardia Inc (MYOK) Insider Joseph Lambing Sells 5,000 Shares of Stock” was first reported by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this piece on another website, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The original version of this piece can be accessed at https://stocknewstimes.com/2018/01/17/myokardia-inc-myok-insider-joseph-lambing-sells-5000-shares-of-stock.html.

About Myokardia

MyoKardia, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics.

Insider Buying and Selling by Quarter for Myokardia (NASDAQ:MYOK)

Receive News & Ratings for Myokardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myokardia and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply